ArticleTurkish journal of medical sciences2021
Giant hepatic hemangioma treatment with transcatheter arterial embolisation and transcatheter arterial chemoembolisation; Comparative results
Article in Turkish journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Synchronous regression of nontarget hepatic hemangiomas following direct sclerotherapy of a symptomatic giant hemangioma: A report of two cases.Radiology case reports · 2026Article
- [Surgical management of giant hemangiomas in the caudate lobe: an overview on the intraoperative management and role of artificial intelligence (AI) in improvement of the surgical results].Chirurgie (Heidelberg, Germany) · 2025Article
- Resistant Hilar Stricture Following Transarterial Bleomycin-Lipiodol Embolization for a Large Hepatic Hemangioma.ACG case reports journal · 2025Article
- Endovascular treatment of giant hepatic hemangiomas: a systematic review and meta-analysis.Jornal vascular brasileiro · 2025Review
- Microwave ablation versus bleomycin-lipiodol emulsion with gelatin sponge embolization for hepatic hemangioma: efficacy and recovery outcomes in a retrospective cohort study.American journal of cancer research · 2025Article
- Reconsideration of the clinical management of hepatic hemangioma.World journal of gastrointestinal surgery · 2024Article
- Long-Term Outcomes of Transarterial Chemoembolization of Giant Liver Hemangiomas with Lipiodol-Bleomycin Emulsion.Cardiovascular and interventional radiology · 2024Article
- Hepatic Hemangioma: Review of Imaging and Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients.BMC pediatrics · 2024Article
- Safety and Feasibility of Transarterial Bleomycin-Lipiodol Embolization in Patients with Giant Hepatic Hemangiomas.Medicina (Kaunas, Lithuania) · 2023Article
- Kasabach-Merritt syndrome complicating a giant hemangioma of the liver: A case report.Radiology case reports · 2023Article
- Transarterial embolization for rare spontaneous subacute intratumoral hemorrhage of hepatic hemangioma: a case report and literature review.Translational cancer research · 2022Article
- Medium and Long-Term Outcome of Superselective Transcatheter Arterial Embolization with Lipiodol-Bleomycin Emulsion for Giant Hepatic Hemangiomas: Results in 241 Patients.Journal of clinical medicine · 2022Article
- Effect of Perioperative Comprehensive Nursing Intervention on Transcatheter Arterial Chemoembolization in Patients with Primary Hepatic Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Treatment of hepatic hemangiomas is a controversial topic, and traditional treatment is surgical excision. Transcatheter arterial embolisation (TAE) and transcatheter arterial chemoembolisation (TACE) have been reported as minimally invasive treatment methods. To the best of our knowledge, there are no studies comparing use of TACE and TAE for hepatic hemangioma treatment. The aim of the study is to compare symptom resolution, size reducing effects, and complications of TACE and TAE for the treatment of giant hepatic hemangiomas. Materials and methods: A total of 104 patients underwent TACE using bleomycin, and 108 patients underwent TAE. The patients were followed-up for 2 year and follow-up images at 6 months, 12 months, and 24 months were acquired. Lesion volumes in both follow-up images were calculated. The patients were examined for any possible procedure related complications as well as the status of their initial symptoms. Results: The shrinkage period was determined to have ended after 12. month in both groups. The results of the two-way mixed ANOVA showed that there was significant main effect of procedure type (p ≤ 0.001) on hemangioma volumes. Similarly, there was a significant interaction between procedure and time (p ≤ 0.001). Conclusion: Both methods are effective in symptomatic relief in properly selected patients. However, TACE causes greater volume reduction with less pain and, therefore, is the better endovascular treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.